Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.

2.

In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.

Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE.

Antimicrob Agents Chemother. 2013 Feb;57(2):796-803. doi: 10.1128/AAC.00980-12. Epub 2012 Nov 26.

3.

Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.

J Infect Dis. 2012 Aug 1;206(3):442-52. doi: 10.1093/infdis/jis372. Epub 2012 May 25.

4.

Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

Seyedmousavi S, Brüggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW.

J Antimicrob Chemother. 2013 Feb;68(2):385-93. doi: 10.1093/jac/dks402. Epub 2012 Nov 5.

5.

Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.

6.

In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.

Krishnan-Natesan S, Wu W, Chandrasekar PH.

Diagn Microbiol Infect Dis. 2012 Jun;73(2):135-7. doi: 10.1016/j.diagmicrobio.2012.02.003.

PMID:
22608136
7.

Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Meletiadis J, Al-Saigh R, Velegraki A, Walsh TJ, Roilides E, Zerva L.

Antimicrob Agents Chemother. 2012 Jan;56(1):403-10. doi: 10.1128/AAC.00662-11. Epub 2011 Nov 7.

8.

Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.

Seyedmousavi S, Brüggemann RJ, Melchers WJ, Verweij PE, Mouton JW.

Antimicrob Agents Chemother. 2013 Jan;57(1):303-8. doi: 10.1128/AAC.01430-12. Epub 2012 Oct 31.

9.

Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2009 May;53(5):2005-13. doi: 10.1128/AAC.01556-08. Epub 2009 Feb 23.

10.

Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.

Cafini F, Sevillano D, Alou L, Gómez-Aguado F, Corcuera MT, González N, Guinea J, Prieto J.

Rev Esp Quimioter. 2012 Mar;25(1):47-55.

11.

Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Perkhofer S, Jost D, Dierich MP, Lass-Flörl C.

Antimicrob Agents Chemother. 2008 May;52(5):1873-5. doi: 10.1128/AAC.01572-07. Epub 2008 Mar 17.

12.

Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Galiger C, Brock M, Jouvion G, Savers A, Parlato M, Ibrahim-Granet O.

Antimicrob Agents Chemother. 2013 Jul;57(7):3046-59. doi: 10.1128/AAC.01660-12. Epub 2013 Apr 15.

13.

Echinocandin antifungal drugs in fungal infections: a comparison.

Chen SC, Slavin MA, Sorrell TC.

Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Review. Erratum in: Drugs. 2011 Jan 22;71(2):253.

PMID:
21175238
14.

Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Elefanti A, Mouton JW, Verweij PE, Tsakris A, Zerva L, Meletiadis J.

Antimicrob Agents Chemother. 2013 Oct;57(10):4656-63. doi: 10.1128/AAC.00597-13. Epub 2013 Jul 15.

15.

Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.

Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW.

Antimicrob Agents Chemother. 2010 Nov;54(11):4758-64. doi: 10.1128/AAC.00606-10. Epub 2010 Aug 23.

16.

Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Lewis RE, Albert ND, Kontoyiannis DP.

Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.

17.

In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.

Al-Saigh R, Elefanti A, Velegraki A, Zerva L, Meletiadis J.

Antimicrob Agents Chemother. 2012 Oct;56(10):5321-7. doi: 10.1128/AAC.00549-12. Epub 2012 Aug 6.

18.

Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.

Salas V, Pastor FJ, Calvo E, Sutton DA, Fothergill AW, Guarro J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1404-8. doi: 10.1128/AAC.01331-12. Epub 2013 Jan 7.

19.

Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21.

20.

Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4146-53. doi: 10.1128/AAC.00141-12. Epub 2012 May 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk